Literature DB >> 29039081

Proteasome dysregulation in human cancer: implications for clinical therapies.

Yulin Chen1, Yanan Zhang1, Xing Guo2.   

Abstract

Cancer cells show heightened dependency on the proteasome for their survival, growth, and spread. Proteasome dysregulation is therefore commonly selected in favor of the development of many types of cancer. The vast abnormalities in a cancer cell, on top of the complexity of the proteasome itself, have enabled a plethora of mechanisms gearing the proteasome to the oncogenic process. Here, we use selected examples to highlight some general mechanisms underlying proteasome dysregulation in cancer, including copy number variations, transcriptional control, epigenetic regulation, and post-translational modifications. Research in this field has greatly advanced our understanding of proteasome regulation and will shed new light on proteasome-based combination therapies for cancer treatment.

Entities:  

Keywords:  Cancer; Copy number; DNA methylation; Immunoproteasome; Post-translational modification; Proteasome; Transcription factor; microRNA

Mesh:

Substances:

Year:  2017        PMID: 29039081     DOI: 10.1007/s10555-017-9704-y

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  12 in total

1.  Prognostic prediction and gene regulation network of EIF2S2 in hepatocellular carcinoma based on data mining.

Authors:  Piyou Ji; Haitao Wang; Yu Cheng; Shaohua Liang
Journal:  J Gastrointest Oncol       Date:  2021-12

Review 2.  Neural is Fundamental: Neural Stemness as the Ground State of Cell Tumorigenicity and Differentiation Potential.

Authors:  Ying Cao
Journal:  Stem Cell Rev Rep       Date:  2021-10-29       Impact factor: 5.739

Review 3.  Therapeutic targeting of BAG3: considering its complexity in cancer and heart disease.

Authors:  Jonathan A Kirk; Joseph Y Cheung; Arthur M Feldman
Journal:  J Clin Invest       Date:  2021-08-16       Impact factor: 19.456

4.  Use of signals of positive and negative selection to distinguish cancer genes and passenger genes.

Authors:  László Bányai; Maria Trexler; Krisztina Kerekes; Orsolya Csuka; László Patthy
Journal:  Elife       Date:  2021-01-11       Impact factor: 8.140

Review 5.  Methods for the discovery of small molecules to monitor and perturb the activity of the human proteasome.

Authors:  Marianne E Maresh; Andres F Salazar-Chaparro; Darci J Trader
Journal:  Future Med Chem       Date:  2020-12-04       Impact factor: 3.808

6.  Integrated genomic analysis of proteasome alterations across 11,057 patients with 33 cancer types: clinically relevant outcomes in framework of 3P medicine.

Authors:  Na Li; Xianquan Zhan
Journal:  EPMA J       Date:  2021-09-30       Impact factor: 6.543

Review 7.  Opportunities and Challenges for Antibodies against Intracellular Antigens.

Authors:  Xiaofeng Yang; Shenxia Xie; Xiaomei Yang; Juan C Cueva; Xiaoqiong Hou; Zhuoran Tang; Hua Yao; Fengzhen Mo; Shihua Yin; Aiqun Liu; Xiaoling Lu
Journal:  Theranostics       Date:  2019-10-15       Impact factor: 11.556

8.  Prognostic Value of SLC4A4 and its Correlation with Immune Infiltration in Colon Adenocarcinoma.

Authors:  Xiaoli Chen; Jianing Chen; Yan Feng; Wei Guan
Journal:  Med Sci Monit       Date:  2020-09-19

9.  Gene Profiling in Patients with Systemic Sclerosis Reveals the Presence of Oncogenic Gene Signatures.

Authors:  Marzia Dolcino; Andrea Pelosi; Piera Filomena Fiore; Giuseppe Patuzzo; Elisa Tinazzi; Claudio Lunardi; Antonio Puccetti
Journal:  Front Immunol       Date:  2018-03-06       Impact factor: 7.561

Review 10.  A Driver Never Works Alone-Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer.

Authors:  Maria Grzes; Magdalena Oron; Zuzanna Staszczak; Akanksha Jaiswar; Magdalena Nowak-Niezgoda; Dawid Walerych
Journal:  Cancers (Basel)       Date:  2020-06-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.